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Background.Although advances in treatment have dramatically improved short-term graft survival and acute rejection in kidney
transplant recipients, long-term graft outcomes have not substantially improved. Transplant recipients also have a considerably
increased risk of cancer, cardiovascular disease, diabetes, and infection, which all contribute to appreciable morbidity and prema-
ture mortality. Many trials in kidney transplantation are short-term, frequently use unvalidated surrogate endpoints, outcomes of
uncertain relevance to patients and clinicians, and do not consistently measure and report key outcomes like death, graft loss, graft
function, and adverse effects of therapy. This diminishes the value of trials in supporting treatment decisions that require individual-
level multiple tradeoffs between graft survival and the risk of side effects, adverse events, and mortality. The Standardized Out-
comes in Nephrology-Transplantation initiative aims to develop a core outcome set for trials in kidney transplantation that is based
on the shared priorities of all stakeholders.Methods. This will include a systematic review to identify outcomes reported in ran-
domized trials, a Delphi survey with an international multistakeholder panel (patients, caregivers, clinicians, researchers, policy
makers, members from industry) to develop a consensus-based prioritized list of outcome domains and a consensus workshop
to review and finalize the core outcome set for trials in kidney transplantation. Conclusions. Developing and implementing a
core outcome set to be reported, at a minimum, in all kidney transplantation trials will improve the transparency, quality, and rele-
vance of research; to enable kidney transplant recipients and their clinicians to make better-informed treatment decisions for im-
proved patient outcomes.
(Transplantation Direct 2016;2: e79; doi: 10.1097/TXD.0000000000000593. Published online 19 May 2016.)
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Advances in transplantation medicine have led to sub-stantial improvement in short and intermediate out-
comes in kidney transplant recipients worldwide with a
1-year graft survival rate exceeding 95% in some countries.1-5
However, major hurdles to the success of kidney transplanta-
tion persist. Long-term graft survival has remained largely
unchanged over the past few decades.2,6-11 For recipients
with a functioning graft 1 year after transplant, their 10-year
graft survival is estimated to be 50% to 70%.6,10,12,13 Fur-
thermore, long-term immunosuppression leads to adverse
outcomes including cancer, cardiovascular disease, diabetes,
and infection—all major causes of premature death in re-
cipients.8,11,14-18 In this complex setting, decision making
should be informed by clinical trials that measure and report
outcomes of relevance to patients and clinicians.
Unfortunately, many trials in kidney transplantation are
short-term, focused on immunosuppression only, and fre-
quently use surrogate endpoints, such as serum creatinine
and glomerular filtration rate, because they require a smaller
sample size and less time and resources to determine treat-
ment efficacy.19 However, these outcomes are largely un-
validated, ill defined, vary widely across trials, and may not
be meaningful or directly relevant to patients.19-23 Such
problems have important implications because patients and
clinicians make treatment decisions that require individual-
level and multiple tradeoffs between graft survival and the
risk of side effects, adverse events, andmortality.20,24 Regula-
tory agencies may also be required to approve products on
the basis of unvalidated and/or short-term surrogate end-
points.19 In recent years, there has been a surge in the number
of biomarkers used to define acute rejection, delayed graft
function, progression of native kidney disease, and late allo-
graft injury,25-30 but the problem of validation has largely
remained.6,29
There is substantial heterogeneity in the myriad of out-
comes in trials in kidney transplantation, and incomplete
reporting of outcomes can render estimates of treatment ef-
fect unreliable. Findings from a recent systematic review of
trials in kidney transplantation indicated that only 79%
provided complete reports of death, less than half reported
time to death, and complete reports for graft function were
infrequent with 35% and 28% trials reporting estimated
glomerular filtration rate and creatinine, respectively. Simi-
larly, studies have shown that kidney function has been
assessed using different outcome measures and at varying
time points.31,32
As in most research, there is a tendency for trialists in kid-
ney transplantation to measure and report outcomes for rea-
sons of feasibility and efficiency rather than relevance to
patients and clinicians. The mismatch between the outcomes
of relevance to stakeholders, such as patients and clinicians,
compared with what is routinely measured and reported is
apparent across medical specialties including kidney trans-
plantation. Although graft loss, mortality, cancer, diabetes,
cardiovascular disease, and infection have been shown to
be of greatest importance to patients,20,24 long-term studies
in kidney transplantation still primarily measure and report
surrogate endpoints, such as kidney function (serum creati-
nine, creatinine clearance) and graft rejection. These surro-
gate endpoints may not be associated with clinical outcomes.
Immunosuppressive medications are potentially harmful,
increase the risk of comorbidities and may cause severe acute
side effects that impair quality of life (QoL).24 These adverse
outcomes amplify the treatment burden for patients and can
potentially lead to nonadherence, which is associated with a
7-fold increase in the risk of graft failure.33,34 Yet, only 2%
of trials of immunosuppression in kidney transplantation
report QoL outcomes, and 95% of these QoL outcomes fa-
vored the intervention, strongly suggestive of a major out-
come reporting bias.21 Reliable evidence for treatment
decision-making based on QoL outcomes is lacking in kid-
ney transplantation, and the inability to address patient pri-
orities and concerns can contribute to nonadherence.
The problems with outcome selection and reporting are
prevalent and increasingly recognized as a major cause of in-
efficiency and waste in biomedical research across all medical
disciplines.35 Many initiatives have been established world-
wide to develop core outcome sets—an agreed minimum set
of standardized outcomes that should be measured and re-
ported in all trials for a specific clinical area (Figure 1).36-39
Core outcome sets can minimize reporting bias, promote
consistency across trials to enable direct comparisons of the
effect of different intervention, and ensure outcomes are rele-
vant and important to patients and health professionals who
make health care decisions.36,37,39,40 TheOutcomeMeasures
in Rheumatology (OMERACT) consensus initiative com-
menced in 1992 and has been at the forefront in engaging pa-
tients, providers, and policy makers to develop core outcome
sets for clinical trials in rheumatology that has helped to im-
prove the completeness of outcome reporting in trials.41–43
Then, in 2010, the Core OutcomeMeasures for Effectiveness
Trials was launched to foster the development and implemen-
tation of core outcome sets.37,40
In kidney transplantation, there is increasing recognition of
the need to develop core outcomes spurring some efforts to re-
view outcomes used in trials in kidney transplantation.22,44-46
The Standardized Outcomes in Nephrology (SONG) initiative
was recently formed to establish core outcomes across the
full spectrum of chronic kidney disease with an initial focus
on hemodialysis.47 The SONG-Tx project aims to establish
a core outcome set for trials in kidney transplantation and
other types of research including observational studies (eg,
registries, quality indicators for clinical care).
MATERIALS AND METHODS
The SONG-Tx project involves 3 phases: systematic re-
view, international online Delphi survey, and a consensus
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workshop (Figure 2). The methods detailed below are
adapted from the processes used in SONG-Hemodialysis,
and the OMERACT48 methodological framework that has
been recognized by the World Health Organization49 as a
valid approach for developing core outcomes.
Phase 1: Systematic Review of Outcome Domains
Reported in Randomized Controlled Trials of
Interventions for Kidney Transplant Recipients
A systematic review will identify and compare outcome
domains and measures reported in randomized controlled
trials (RCTs) of interventions for adult kidney transplant
recipients.
Search Strategy
We will search the Cochrane Database of Systematic re-
views to identify all systematic reviews that included at least
1 RCT involving adult kidney transplant recipients. We will
retrieve the full text article of all RCTs included in the sys-
tematic review, and also search for all additional articles
published from the same trial using key word searches in
electronic databases (MEDLINE, Embase) and trial regis-
tries. No date or language restrictions will be applied.
Types of Studies
For feasibility, the Cochrane Database of Systematic re-
views will be used as a sampling frame to identify RCTs in
kidney transplantation, as has been done in previous analysis
of outcomes reporting in RCTs.22,50 Based on a preliminary
search, we expect that more than 300 RCTs will be included.
Types of Interventions
Any intervention (including but not limited to surgical,
pharmacological [immunosuppression, antibiotics, antifun-
gal, antivirals, diuretics, statins, vaccines], psychosocial and
lifestyle) for kidney transplant recipients will be eligible.
Types of Participants
Adult kidney transplant recipients (aged ≥ 18 years).
Exclusion Criteria
Randomized controlled trials that included other solid or-
gan or tissue transplant recipients (eg, lung, liver, heart, pan-
creas, bone marrow) will be excluded as our primary focus is
on kidney transplantation.
Eligibility of Studies
Two reviewers (B.S., N.E.) will independently assess all re-
cords obtained from the searches. Full texts of all potentially
relevant systematic reviews and RCTs will be assessed inde-
pendently by the 2 reviewers, and any disagreement on
the eligibility of included studies will be resolved through
consultation with a third reviewer (A.T.).
Data Extraction
One reviewer (B.S.) will extract characteristics of all the tri-
als including: first author, date of publication, country/ies in
which the trial was conducted, sample size, participant char-
acteristics (range and mean age, time since transplant, sex),
trial duration, name and type of intervention (eg, surgical,
pharmacological, psychosocial, lifestyle), and all outcomes
as reported in the trial (including definitions, tools for mea-
surement, thresholds, time points or time frames formeasure-
ment, change in level or percentage, scores). Two reviewers
(N.E., A.T.) will cross check the data extraction.
Data Analysis and Presentation
The data will be entered intoMicrosoft Excel to assist with
data management, tabulation, and analysis. Author B.S. will
group all similar outcomes into appropriate outcome do-
mains, which will be reviewed and discussed by the SONG-
Tx Steering Group (J.R.C. [Chair], K.B., J.G., M.A.J., L.M.,
T.P.P., D.R., L.R., A.W., G.W.] and SONG Executive Com-
mittee (J.C.C., S.C., J.G., T.H., B.H., B.M., P.T., W.V.B.,
D.C.W.,W.C.W., A.T.). The outcome domains will be broadly
classified as surrogate, clinical, or patient-reported outcomes.
We will identify the number of trials that reported each out-
come domain. For each outcome domain, we will assess the
number of different outcomes (including measures) and the
number of trials that assessed each specific outcome and per-
form statistical analyses using the software package R (ver-
sion 3.2.3).
Phase 2: International Online Delphi
Consensus Survey
An international online Delphi survey will be conducted to
generate consensus on the outcome domains that are most
important to all stakeholder groups. The Delphi has been
used to obtain reliable consensus on core outcome sets across
a range of health conditions.51-54 This technique involves 2
or 3 rounds of surveys completed sequentially and anony-
mously by a panel of experts with experience or expertise
FIGURE 1. Conceptual schema of core outcomes.
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FIGURE 2. SONG-Tx process.
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on the topic38,55 and allows feedback of individual contribu-
tions of knowledge, information, and perspectives; assess-
ment of the group view; and opportunities for respondents
to revise their opinions.56 The controlled communication in
this process minimizes direct confrontation and allows in-
dividual respondents to express independent thought and en-
ables equitable contribution from all participants. This study
has been approved by the Human Research Ethics Commit-
tee of The University of Sydney (2015-228).
Participants and Recruitment
There is no universal agreement on the “minimum” or
appropriate sample size for a Delphi panel. The majority
Delphi of studies in core outcome development have in-
cluded less than 200 respondents. Given the large health
professional and consumer networks in kidney transplanta-
tion and to achieve broad engagement internationally, our
minimum target sample size will be 500 respondents with
at least 250 patients with chronic kidney disease (either with
a functioning graft, on dialysis having lost a kidney trans-
plant, or waiting for a kidney transplant)/family members/
living kidney donors) to ensure a sample size balance be-
tween patients/family members/donors and health profes-
sionals. We will aim to recruit nephrologists and surgeons
(minimum n = 150); nursing and allied health professionals
(n = 50); and policy makers (including regulators), re-
searchers, and representatives from industry (n = 50); who
have experience, expertise, or interest in kidney transplant
recipient outcomes.
Purposive sampling to obtain a maximum variation in the
demographics, clinical characteristics (patients), and profes-
sional experiences and roles (health professionals), and
snowballing strategies (where participants can nominate or
extend an invitation to other relevant stakeholder members
to participate) will be used. Patients/family members will be
recruited through participating hospital/university institu-
tions of the SONG Executive, SONG-Tx Steering Group
and investigators, patient/consumer organisations, and the
SONG Initiative database. Health professionals will be re-
cruited via the collegial networks of the investigators and
professional transplantation and nephrology societies.
Data Collection
Generating the List of Outcomes
The Delphi survey will include outcome domains from the
systematic review of outcomes reported in RCTs (phase 1).
To ensure that patient-important outcomes are considered,
we will also identify outcomes from studies that involved pa-
tients in prioritizing or reporting outcomes in kidney trans-
plantation. The key studies that will be used to directly
inform the Delphi are outlined in the following.
A recent nominal group technique study conducted with
57 kidney transplant recipients who participated in 8 nomi-
nal groups in Australia to identify and rank outcomes rele-
vant to immunosuppressant medications.20 All outcomes
identified will be considered for inclusion in the Delphi. The
top 10 ranked outcomes overall were: kidney rejection lead-
ing to graft loss, kidney function, damage to other organs,
cancer (all), diabetes, skin cancer, cardiovascular disease, in-
fection, weight gain and excessive appetite, and in addition
the top 5 psychosocial or physical symptoms were: impact
on family, depression, impact onwork, gastrointestinal prob-
lem, and concentration and memory.20 Potential outcomes
for the Delphi survey will also be extrapolated from a system-
atic review of qualitative studies on the motivations, chal-
lenges, and attitudes to self-management in kidney transplant
recipient (eg, graft function, graft rejection, alopecia, pain,
anxiety, cardiovascular disease, diabetes, cancer, mouth ulcers,
acne, cataracts, diarrhoea, physical appearance).57
A systematic review of patient-reported QoL outcomes in
trials of immunosuppressive agents in kidney transplanta-
tions identified 2 kidney transplant-specific instruments (Kid-
ney Transplant Questionnaire [physical symptoms, fatigue,
uncertainty/fear, appearance, emotional status],58 and a vi-
sual analogue scale to assess impact of disease) and 21
symptom-specific instruments (eg, depression, gastrointesti-
nal problems, physical appearance, physical well-being).21
Attributes from these will be used to inform the development
of the list of outcomes for the Delphi.
All outcomes will include a plain language definition. The
survey will be reviewed by the SONG Executive and SONG-
Tx Steering Group, which includes kidney transplant recipi-
ents, and piloted with at least 10 kidney transplant recipients.
Survey Administration
All participants must register their name and email address
via www.songinitiative.org byMarch 2016 to receive a stan-
dard study information sheet. Informed consent will be ob-
tained from all participants. The surveys will be completed
online via LimeSurvey. Each participant will be given a
unique identifier so their responses from rounds 1 to 3 can
be linked anonymously. At least 3 reminders will be sent to
the participants during the Delphi Rounds in an attempt to
retain at least a 70% response rate across all 3 rounds. Partic-
ipants who complete all 3 rounds will receive a copy of the
preliminary results to provide feedback and comment.
Delphi Survey Round 1
Participants will be asked to rate the importance of out-
come domain for research in kidney transplantation (approx-
imately 35) using the GRADE 9-point Likert scale.59 The
visual scale used for each outcome will indicate ratings 1 to
3 as “limited importance”; “4 to 6 as “important, but not
critical”; and 7 to 9 as “critical importance.” An option “un-
sure”will also be provided. Responses to the rating questions
will be mandatory. Participants can provide comments in a
free-text box under each outcome. The sequence of outcomes
shown will be randomized to minimize ordering bias. At the
end of the round, participants can suggest new outcomes. All
new outcomes that are suggested by more than 10% of par-
ticipants and that do not overlap or duplicate already pre-
sented outcomes will be recoded by at least 2 investigators
(N.E., B.S.) and reviewed by the SONG-Tx Steering Group,
then carried through round 2.
Depending on distribution of scores across all out-
comes, an outcome with a median and mean of more than
7 (with ≥ 70% of participants in both patient/family
member/donor and health professionals rating the outcome
7-9; based on the OMERACT criteria for consensus in) will
be retained in round 2. Any outcomes that were not retained
in subsequent rounds will still be considered in the research
agenda (Figure 1).
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Delphi Survey Round 2:
In round 2, participants will be presented with a column
graph of the distribution of scores for each outcome for the fol-
lowing groups: (1) patients/family members/donors, (2) health
professionals, and (3) all participants (with scores weighted
evenly between groups). An explanation of how to read the
graph will be provided to ensure that participants can under-
stand and interpret the graph clearly. They will also see com-
ments from round 1 by patients/family members/donors and
health professionals. In the rating scale, their own response
from the previous round will be highlighted. Participants will
rerate each outcome and any additional outcomes identified
in round 1 using the same GRADE 9-point Likert scale. A
free-text box will be provided for participants to explain rea-
sons for their rating or to provide responses to the comments.
An outcome with a median and mean of more than 7
(with ≥ 70% of participants in both patient/family member/
donor and health professionals rating the outcome 7-9) will
be included in round 3.
Delphi Survey Round 3
In this final round, participants will see the distribution of
scores for each outcome for all participants and by stake-
holder groups and comments from round 2. Participants will
see their own score from round 2 highlighted in the rating
scale and rerate all outcomes. A free-text box will be pro-
vided for additional comments. In the final section of the sur-
vey, participants will be asked to complete a forced ranking
exercise. They will be presented with a list of all outcomes
to arrange into a list in order of importance (top being most
important).
Data Analysis
For all 3 rounds, we will summarize the distribution of
scores and calculate the mean, median, and proportion for
ratings and rankings of each outcome. According to the
OMERACT prespecified definition of “consensus” for out-
comes to be included in the core set, the outcome must have
at least 70% participants scoring 7 to 9 and less than 15%
of participants scoring as 1 to 3.48 Based on previous initia-
tive, a core set includes 3 to 5 outcomes for feasibility. How-
ever, it is possible that more than 5 outcomes will meet the
OMERACT threshold for inclusion. Therefore, the identifi-
cation of preliminary core outcome domains will also be
based onmeans,medians, and proportions in round 3, which
will be validated against the OMERACT cutoffs based on
proportions. Because it may be necessary to define consensus
post hoc to some extent, the preliminary outcomes with the
rationale and threshold for inclusion will be detailed in a
plain language report. This will be discussed at the consensus
workshop (phase 3).
Phase 3: Consensus Workshop
A consensus workshopwill be convenedwith stakeholders
to comment and critique the identification of core outcomes
(including the potential set of core outcomes) and to discuss
strategies for the development of outcome measures and im-
plementation. A member of the SONG-Tx Steering Group
will chair the session. We aim to have a minimum of 60 at-
tendees, with at least 20 patients/family members. Health
professionals with a range of clinical experience in kidney
transplantation (nephrologists, surgeons, nursing, and allied
health professionals), expertise in research (epidemiology,
clinical trials in kidney transplantation, registries, quality im-
provement), and leadership or advisory roles in major re-
search and policy organizations (including regulators) and
industry will be invited to attend.
Before the workshop, we will send participants a copy of
the results from phase 1 and phase 2, so they can reflect on
the results to date and be better prepared to contribute their
opinions during the workshop. The workshop will include
3 sessions:
Session 1: Introduction
We will provide a brief introduction to the SONG-Tx initia-
tive and present the details of the SONG-Tx process and re-
sults from phase 1 and phase 2 and the preliminary core
outcome set and proposed threshold for inclusion.
Session 2: Breakout groups
Participants will be allocated to 1 of 5 breakout groups with
up to 12 participants in each group (including a facilitator
and cofacilitator). Mixed stakeholder groups with at least
2 patients/family members will be convened to encourage a
richer exchange of ideas, explanations of similar or different
opinions, and breadth of discussion. A trained facilitator will
ask participants to discuss the identification and implementa-
tion of core outcomes, and ensure cooperative, respectful and
inclusive discussion. All facilitators will attend a briefing ses-
sion and will be provided with a question guide.
Session 3: Plenary discussion
The groups will reconvene to engage in a broader discussion
moderated by the workshop chair. A member from each
breakout group will present a brief summary of their discus-
sion. The wide group will be invited to give their opinions, re-
flections on the issues raised by other groups. The moderator
will summarize key similarities and differences in the points
raised across groups.
Finalization of Core Outcome Domains
The SONG-Tx process (phase 1 to phase 3) and proposed
outcomes will be published in a plain language report for cir-
culation to the participants in the Delphi (phase 2) and con-
sensus workshop (phase 3), circulated to stakeholder groups
andmade available on the website for 3 weeks to obtain pub-
lic comment. All feedbacks will be reviewed by the SONG-Tx
Steering Group and SONG Executive Committee to finalize
the SONG-Tx core outcome set.
DISCUSSION
The SONG-Tx project uses a validated and transparent
process that enables broad stakeholder engagement to de-
velop a consensus-based prioritized set of core outcome do-
mains for trials in kidney transplantation that can also be
applied to other research contexts including registry studies
and quality measurement activities. For each of the core out-
come domains, we will identify or develop core outcome
measures using the OMERACT filter to ensure that they
are valid, discriminative, and feasible.60 We will develop
and apply implementation strategies in consultation with
key stakeholders so that the core outcomes will be progres-
sively translated into all trials and research.
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Consistent and complete reporting of outcomes that are
highly important to all stakeholder groups is likely to im-
prove the quality and relevance of the research evidence to
better support patients and clinicians in making informed
treatment decisions in kidney transplantation. The core out-
come set may also serve as a catalyst in driving the research
agenda to focus on outcomes that really matter to patients
and health care providers.
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